Construction and validation of a prognostic nomogram for ductal adenocarcinoma of the prostate: A population-based study
Cheng Li,Zhengqiang Wan,Yinglei Wang,Guangming Shan,Baoquan Yang
DOI: https://doi.org/10.1097/md.0000000000036877
IF: 1.6
2024-01-13
Medicine
Abstract:Prostate cancer (PCa) is one of the most common malignancies and the 5th leading cause of cancer deaths in men worldwide. In 2020, there were 1414,249 new diagnoses and 375,000 deaths annually worldwide. [ 1 , 2 ] The pathogenesis of PCa is currently unknown, but studies suggest a strong genetic link, while race, obesity, persistently elevated testosterone levels, and high blood pressure increase the risk of developing PCa. [ 3 , 4 ] In 2016, the World Health Organization classification of tumors of the urinary system and male genital organs identified rare histological sub-types of PCa other than the most common acinar adenocarcinoma (APC), including neuroendocrine tumors, basal cell carcinoma, adenosquamous carcinoma and ductal adenocarcinoma of the prostate (DAC). [ 5 ] Of these, DAC is a rare sub-type of PCa, with an incidence of <1%, but remains the second most common sub-type of PCa. [ 6 ] DAC was developed by Melicow in 1967 and was initially referred to as "endometrioid carcinoma" or "papillary carcinoma" because of its early pathological resemblance to endometrial cancer. [ 7 ] The prognosis is often poor due to the lack of specific treatment. [ 8 ] DAC is also more likely to metastasize to less common sites than APC, including the lung, brain and testis. [ 9 , 10 ] The clinical presentation of DAC is mostly hematuria, which lacks specific clinical features. At the time of diagnosis, prostate-specific antigen (PSA) levels are usually low in patients with DAC. [ 11 , 12 ] Decision curve analysis (DCA) is difficult to diagnose in the early stages of the disease and can be easily missed or even misdiagnosed, with most diagnoses being made at a late stage, thus missing the best time for treatment and resulting in a poor prognosis.
medicine, general & internal